What is Celldex Therapeutics's net income?

Celldex Therapeutics (CLDX) reported net income of -$78.69M in Q1 2026.

How has Celldex Therapeutics's net income changed year-over-year?

Celldex Therapeutics's net income decreased by 46.3% year-over-year, from -$53.8M to -$78.69M.

Over 4 years (2021 to 2025), Celldex Therapeutics's net income has grown at a 38.4% compound annual growth rate (CAGR), from -$70.51M to -$258.76M.

Revenue$15.0K-97.8%

Operating income-$84.4M-34.6%

Net income-$78.7M-46.3%

EPS (diluted)-$1.18-45.7%

Cash & equivalents$35.7M+109%

Total debt$1.9M-44.3%

Total equity$456.2M-35.1%

Total assets$511.3M-30.9%

Operating cash flow-$65.6M-20.6%

CapEx$1.6M+518%

Free cash flow-$67.2M-23.0%

Market cap$2.65B+75.2%

Operating margin-35,688.5%-39,114pp

Net margin-32,753.6%-35,519pp

FCF margin-26,125.8%-28,907pp

Return on equity-48.9%-498pp

Debt / equity0×0.0×

Current ratio8.9×-12.7×

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

What is Celldex Therapeutics's net income?: Celldex Therapeutics (CLDX) reported net income of -$78.69M in Q1 2026.
How has Celldex Therapeutics's net income changed year-over-year?: Celldex Therapeutics's net income decreased by 46.3% year-over-year, from -$53.8M to -$78.69M.
What is the long-term trend for Celldex Therapeutics's net income?: Over 4 years (2021 to 2025), Celldex Therapeutics's net income has grown at a 38.4% compound annual growth rate (CAGR), from -$70.51M to -$258.76M.